查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858273

陰道炎治療市場依治療方法、給藥途徑、產品類型、通路和最終用戶群分類－2025-2032年全球預測

Vaginitis Therapeutics Market by Treatment Type, Route Of Administration, Product Type, Distribution Channel, End User Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，陰道炎治療市場將成長至 56.9 億美元，複合年成長率為 9.44%。

主要市場統計數據
基準年 2024 27.6億美元
預計年份：2025年 30.2億美元
預測年份：2032年 56.9億美元
複合年成長率 (%) 9.44%

這份簡明扼要而又引人入勝的陰道炎治療概述，清楚地闡明了治療的緊迫性、尚未滿足的臨床需求以及相關人員的戰略重點。

陰道炎一直是臨床醫生、支付方和產品開發商的焦點，因為它兼具常見的臨床需求、複雜的診斷難度和不斷變化的患者偏好。以下概述提供了醫療保健和生命科學領域相關人員在製定產品組合決策、臨床開發重點和商業化策略時應考慮的臨床背景和策略因素。

科學突破、病人期望以及醫療服務模式的轉變，正以變革性的力量重塑陰道炎的治療模式。

由於科學、商業和患者主導力量的融合，陰道炎的治療格局正在經歷一場變革。微生物組學和標靶抗真菌藥物的進步正在拓展治療手段，使研發人員能夠擺脫「一刀切」的產品模式，轉而開發針對特定病因和復發因素的干涉措施。

預測美國關稅在2025年對陰道炎治療藥物的供應鏈、價格趨勢和臨床可及性的累積影響

主要經濟體徵收的關稅會對藥品採購、生產和分銷產生連鎖反應，而美國政策預計將在2025年進行調整，因此，整個陰道炎治療價值鏈都需要進行周密的戰略規劃。無論是對原料、成品製劑或包裝組件徵收關稅，進口關稅的變化都會影響採購決策、供應商談判以及生產基地的地理佈局。為此，各組織應預見供應商集中度的變化，並考慮採用多元化採購策略，以降低對單一國家的依賴風險。

提供關於治療領域、給藥途徑、產品類型、配銷通路和人口統計群體等方面的可操作細分資訊，以指導臨床和商業性決策。

陰道炎治療有效細分是商業和臨床策略的基礎，因為它界定了臨床差異化和商業性機會的交會點。治療細分區分了抗真菌療法和益生菌療法。在抗黴菌療法中，又可分為Azole和Polyenes，Azole可進一步細分為Clotrimazole、Fluconazole和Miconazole等關鍵藥物，而Polyenes則包括雙性殺黴素B和製黴菌素。這種治療方法細分至關重要，因為不同類別的藥物在動態、復發情況和抗藥性方面存在差異，從而影響臨床定位和實證醫學證據的需求。

從美洲、歐洲、中東和非洲以及亞太地區的戰略視角出發，確定市場進入和供應優先事項。

區域趨勢對陰道炎治療市場的監管管道、供應鏈物流和患者就醫策略有顯著影響。美洲地區擁有多元化的支付體系和分銷模式，涵蓋了私人和公共採購機制，數位化醫療的普及率也在穩步提升。這些趨勢有利於那些展現出明顯臨床差異化優勢和更高患者依從性的產品，並獎勵那些能夠同時利用機構採購和零售/線上管道的製造商。

不斷發展的陰道炎治療市場中製造商、創新者和經銷商的競爭及企業策略

目前，陰道炎治療市場的競爭優勢取決於臨床差異化、配方創新和分銷靈活性的綜合作用。擁有豐富產品系列的成熟製造商往往利用規模經濟來確保分銷管道暢通和快速補貨。同時，小規模的創新企業通常將臨床差異化、新穎的作用機制和更佳的耐受性視為競爭優勢。企業面臨的策略挑戰包括：投資於強力的對比研究，以證明其產品能夠降低復發率並改善患者報告的療效；以及開發能夠提高患者依從性和保護消費者隱私的包裝和劑型。

為陰道炎治療領域的行業領導者提供具有重大影響的策略建議，以加快患者療效、最佳化產品組合併確保供應鏈的韌性。

我們鼓勵產業領導者制定切實可行的行動計劃，將洞察轉化為臨床、商業和營運領域可衡量的成果。首先，應優先發展能夠產生直接臨床結果和復發數據的研發管道，因為這些終點指標正日益影響支付方和臨床醫生的決策。此外，還應補充以患者為中心的證據，例如依從性、生活品質指標和真實世界中的復發預防數據，以增強您的價值提案。

調查方法進行了全面的概述，解釋了治療分析的資料來源、分析框架、檢驗過程和局限性。

本報告的研究基於三角調查方法，該方法結合了對關鍵相關利益者的訪談、對同行評審臨床文獻的系統性回顧、對監管指南的分析以及對分銷和供應鏈指標的評估。主要資料來源包括對臨床醫生、處方集管理人員、採購人員和產品開發專業人員的結構化訪談，以收集有關臨床需求、證據預期和獲取挑戰的第一手資訊。次要分析整合了臨床試驗結果、指引更新和安全性數據，以確保臨床聲明有已發表的證據支持。

整合策略洞察和視角，將臨床、監管和商業性知識轉化為相關人員可執行的優先事項。

這個總體方案整合了臨床、監管和商業性的洞察，為關注陰道炎治療的相關人員制定了一套連貫的優先事項。無論治療類別或給藥途徑為何，關鍵挑戰顯而易見：能夠大幅降低復發率、提高耐受性並符合患者偏好的治療方法最有可能獲得持續推廣。實現這一目標需要一種綜合方法，將嚴謹的臨床計畫與真實世界證據收集以及支持患者依從性和監測的數位互動策略相結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 快速採用新一代分子診斷技術進行精準的陰道微生物組分析與標靶化治療。
  • 加強旨在恢復復發性陰道炎患者陰道健康菌叢的生物治療產品研發管線
  • 加大對硼酸和非抗生素硼酸酯療法在生物膜破壞方面的投資
  • 非處方抗真菌凝膠配方，添加了黏膜附著性聚合物，以提高患者依從性和療效。
  • 透過整合遠端醫療和數位症狀追蹤應用程式，實現陰道炎治療管道和結果的個人化
  • 利用新一代定序技術對陰道微生物群進行定序和抗藥性基因譜分析，以選擇個人化治療方案。
  • 用於預防復發性細菌性陰道炎的非荷爾蒙微生物群修復產品獲得加速監管核准
  • 一項評估陰道微生物移植作為治療難治性細菌性陰道炎替代療法療效的臨床研究

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 陰道炎治療市場：依治療方法分類

  • 抗真菌治療
    • Azole
      • Clotrimazole
      • Fluconazole
      • Miconazole
    • Polyenes
      • 雙性殺黴素B
      • 制黴菌素
  • 益生菌療法

9. 依給藥途徑分類的陰道炎治療市場

  • 陰道給藥
    • 奶油
    • 凝膠
    • 栓劑
  • 口服
    • 膠囊
    • 藥片
  • 外用藥物
    • 奶油
    • 凝膠
    • 軟膏

第10章 依產品類型分類的陰道炎治療市場

  • 非處方藥
  • 處方藥

第11章 按分銷管道分類的陰道炎治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶細分市場分類的陰道炎治療市場

  • 停經後婦女
    • 46至60歲
    • 60歲或以上
  • 閉經婦女
    • 18至25歲
    • 26至35歲
    • 36至45歲
  • 孕婦

第13章 各地區陰道炎治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的陰道炎治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國陰道炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • The Procter & Gamble Company
    • Bayer Aktiengesellschaft
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Lupin Limited
    • Glenmark Pharmaceuticals Ltd.
    • Cipla Limited
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-8E22B61932BA

The Vaginitis Therapeutics Market is projected to grow by USD 5.69 billion at a CAGR of 9.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.76 billion
Estimated Year [2025] USD 3.02 billion
Forecast Year [2032] USD 5.69 billion
CAGR (%) 9.44%

A concise yet compelling overview of vaginitis therapeutics that frames urgency, clinical unmet needs, and strategic priorities for stakeholders

Vaginitis remains a focal point for clinicians, payers, and product developers because it intersects prevalent clinical need, diagnostic complexity, and a shifting patient preference landscape. The introduction below frames the clinical context and strategic drivers that should inform portfolio decisions, clinical development prioritization, and commercialization strategies for stakeholders across healthcare and life sciences.

Clinically, vaginitis encompasses a spectrum of etiologies that demand divergent therapeutic approaches, ranging from antifungal regimens to probiotic adjuncts aimed at restoring microbiome balance. Diagnostic ambiguity persists in many care pathways, complicating treatment selection and driving patient dissatisfaction. At the same time, advancements in formulation science and increasing acceptance of at-home care pathways have expanded the tactical options available to manufacturers and providers. These trends create both opportunities for differentiated product positioning and risks for commoditization if clinical value is not clearly articulated.

From a strategic perspective, the convergence of regulatory scrutiny, payer emphasis on cost-effectiveness, and digital health enablement is reshaping how therapies progress from concept to clinic. Commercial strategies must therefore integrate clinical evidence generation, real-world outcomes capture, and patient-centric access models to build sustainable adoption. In short, the field calls for an integrated approach that aligns therapeutic innovation with pragmatic deployment in diverse care settings.

Evolutionary forces reshaping the vaginitis treatment landscape through scientific breakthroughs, patient expectations, and shifts in care delivery models

The landscape for vaginitis therapeutics is undergoing transformative shifts driven by converging scientific, commercial, and patient-driven forces. Scientific advances in microbiome science and targeted antifungal pharmacology are broadening the therapeutic toolkit, enabling developers to move beyond one-size-fits-all products toward interventions that address specific etiologies and recurrence drivers.

Concurrently, patients are exerting greater influence over care choices, favoring discreet, convenient, and evidence-backed options that fit into their daily routines. This has accelerated demand for oral and intravaginal formats that deliver rapid symptom relief while fitting home-based treatment paradigms. Digital diagnostics and telehealth are also reshaping early triage and treatment initiation, reducing barriers to care but raising expectations for integrated digital support and clear evidence of clinical benefit.

Commercial dynamics are evolving in parallel: payers and procurement stakeholders increasingly prioritize therapeutic value demonstrated through outcomes and reduced recurrence rates. Manufacturers that invest in robust post-market evidence, adherence support initiatives, and supply chain resilience will be better positioned to secure formulary access and provider endorsement. Taken together, these shifts signal a market that rewards targeted clinical differentiation, patient-centric delivery models, and data-driven value propositions.

Anticipating the cumulative implications of United States tariff actions in 2025 on supply chains, pricing dynamics, and clinical accessibility across vaginitis therapeutics

Tariff actions originating from major economies can have cascading effects across pharmaceutical sourcing, manufacturing, and distribution, and the United States policy adjustments anticipated in 2025 warrant careful strategic planning across the vaginitis therapeutics value chain. Changes in import duties, whether enacted on raw materials, finished dosage forms, or packaging components, can influence procurement decisions, supplier negotiations, and the geographic configuration of production footprints. In response, organizations should anticipate shifts in supplier concentration and consider dual-sourcing strategies to mitigate single-country exposure.

Price pressure may manifest differently across segments; products that are predominantly imported or rely on complex supply chains could see cost passthrough pressures that affect list prices, payer negotiations, and ultimately patient out-of-pocket costs. Moreover, tariff-induced cost variability can compress margins for commoditized therapeutics unless manufacturers proactively redesign supply chains, optimize formulation yields, or transition certain components to domestic production. Regulatory timelines and batch release processes must also be recalibrated when manufacturing relocations occur to prevent interruptions in product availability.

Beyond direct cost implications, tariffs can catalyze strategic responses such as increased vertical integration, regional manufacturing hubs, and greater emphasis on supplier partnerships that lock in long-term pricing and capacity. Stakeholders should therefore adopt scenario-based planning, stress-test procurement and distribution assumptions, and prioritize investments that enhance agility, cost visibility, and continuity of supply to reduce exposure to trade policy volatility.

Actionable segmentation intelligence on therapeutic classes, routes, product types, distribution channels, and demographic cohorts driving clinical and commercial decisions

Effective segmentation is foundational to commercial and clinical strategy in vaginitis therapeutics because it clarifies where clinical differentiation and commercial opportunities converge. Treatment type segmentation distinguishes antifungal therapies from probiotic approaches; within antifungal treatments there are class distinctions between azoles and polyenes, with azoles further segmented by dominant agents such as clotrimazole, fluconazole, and miconazole, while polyenes encompass amphotericin B and nystatin. This therapeutic granularity matters because pharmacodynamics, recurrence profiles, and resistance considerations differ across classes, shaping clinical positioning and evidence generation needs.

Route of administration is another pivotal segmentation axis. Intravaginal delivery subdivides into creams, gels, and suppositories, each offering distinct onset-of-action profiles, adherence implications, and patient preferences. Oral formulations are categorized into capsules and tablets, which present advantages in terms of systemic exposure and convenience but require different safety and labeling considerations. Topical preparations, including creams, gels, and ointments, serve unique roles in symptomatic relief and localized therapy and are evaluated differently by providers and patients.

Product type division between over-the-counter and prescription status impacts promotional approaches, regulatory obligations, and access pathways. Distribution channel segmentation spans hospital pharmacies, online pharmacies, and retail pharmacies, each with unique purchasing behaviors, formulary dynamics, and service expectations. Finally, end user demographic segmentation differentiates post-menopausal women, pre-menopausal women, and pregnant women; these cohorts are further stratified by age bands that influence prevalence, comorbidity profiles, and tolerability concerns. Integrating these segmentation dimensions enables stakeholders to design targeted clinical trials, tailor messaging to specific care settings, and prioritize channels that optimize adoption and adherence.

Regionally differentiated strategic outlooks for the Americas, Europe Middle East and Africa, and Asia-Pacific that inform market access and supply priorities

Regional dynamics exert a profound influence on regulatory pathways, supply logistics, and patient access strategies across the vaginitis therapeutics landscape. The Americas region combines diverse payer systems and distribution models, where private and public procurement mechanisms coexist and where digital care adoption is steadily increasing. These dynamics favor products that demonstrate a clear clinical differentiator or improved adherence, and they reward manufacturers that can navigate both institutional purchasing and retail/online channels.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways requires adaptive market entry playbooks. Some markets demand extensive clinical comparators and health economics evidence, while others prioritize cost-effective, easily deployable solutions. Supply chain complexity and variable cold chain infrastructures in certain geographies also influence product design and packaging decisions. In contrast, the Asia-Pacific region is characterized by rapid adoption of digital health platforms, high-volume demand for both prescription and over-the-counter solutions, and growing local manufacturing capacity. These attributes create opportunities for scalable, low-cost formulations as well as differentiated specialty products targeted at urban centers and digitally enabled patient segments.

Across all regions, local epidemiology, cultural perceptions of women's health, and access to primary care shape uptake. Consequently, regional strategies should align regulatory engagement, distribution partnerships, and patient education initiatives with local healthcare delivery realities to maximize clinical impact and commercial viability.

Competitive dynamics and corporate imperatives for manufacturers, innovators, and distributors competing in the evolving vaginitis therapeutics ecosystem

Competitive positioning in vaginitis therapeutics now hinges on a blend of clinical differentiation, formulation innovation, and distribution agility. Incumbent manufacturers that maintain broad product portfolios often leverage scale to secure channel placement and rapid replenishment, while smaller innovators typically compete on clinical differentiation, novel mechanisms, or superior tolerability profiles. Strategic imperatives for companies include investing in robust comparative evidence that demonstrates reduced recurrence and meaningful patient-reported outcomes, as well as developing packaging and delivery formats that enhance adherence and consumer discretion.

Collaboration between pharmaceutical developers and digital health firms has emerged as an important axis of competitive advantage, enabling bundled offerings that combine pharmacologic therapy with adherence support, symptom tracking, and remote clinician engagement. Moreover, companies that align product development with regulatory pathways for label expansion or OTC switches can unlock new access channels and broaden patient reach. Operationally, securing resilient manufacturing partnerships and flexible contract manufacturing agreements mitigates risk from supply interruptions and tariff-related cost shifts.

Mergers, licensing deals, and strategic alliances remain viable routes to accelerate capability acquisition, whether that entails gaining access to novel probiotic strains, advanced intravaginal delivery platforms, or regional distribution networks. Ultimately, successful companies will integrate clinical excellence with commercial finesse and operational resilience to navigate a competitive and policy-sensitive environment.

High-impact strategic recommendations for industry leaders to accelerate patient outcomes, optimize portfolios, and secure resilient supply chains in vaginitis care

Industry leaders should adopt a set of pragmatic, implementation-focused actions to translate insights into measurable outcomes across clinical, commercial, and operational domains. First, prioritize development pathways that generate head-to-head clinical outcomes and recurrence data, as these endpoints increasingly drive payer and clinician decision-making. Complement clinical programs with patient-centered evidence that captures adherence, quality-of-life metrics, and real-world recurrence prevention to strengthen value propositions.

Second, optimize product portfolios by aligning formulation choices with care settings and patient preferences; for example, invest in discreet intravaginal formats for home treatment, and ensure oral options are supported by clear safety profiles that enable wider primary care adoption. Third, build supply chain resilience through geographic diversification of manufacturing, strategic supplier contracting, and inventory strategies that accommodate tariff volatility and regional demand fluctuations. Fourth, accelerate digital integration by coupling therapies with telehealth-compatible diagnostics and adherence tools, thereby creating stickier patient journeys and enhancing clinical follow-up.

Finally, advance commercial readiness by tailoring distribution strategies across hospital pharmacies, retail points, and online pharmacies, and by developing payer engagement plans that foreground outcomes and economic case narratives. Executed together, these recommendations will help organizations convert scientific and commercial potential into durable clinical impact and market differentiation.

Robust research methodology overview describing data sources, analytical frameworks, validation processes, and limitations underpinning the therapeutic analysis

The research underpinning this report relies on a triangulated methodology that combines primary stakeholder interviews, systematic review of peer-reviewed clinical literature, analysis of regulatory guidelines, and evaluation of distribution and supply chain indicators. Primary inputs include structured interviews with clinicians, formulary managers, procurement leads, and product development experts to capture firsthand perspectives on clinical needs, evidence expectations, and access challenges. Secondary analyses synthesize clinical trial results, guideline updates, and safety profiles to ensure clinical assertions are grounded in the published evidence base.

Data on distribution practices and manufacturing configurations are derived from a combination of public regulatory filings, supply chain disclosures, and industry reports to map typical logistics flows and identify vulnerability points. Analytical frameworks incorporate scenario analysis to evaluate resilience under different trade and policy conditions, as well as cross-segmentation mapping to align product archetypes with distribution channels and end-user cohorts. Validation steps include peer review by subject-matter experts and consistency checks across independent data sources to minimize bias.

Limitations are acknowledged where primary data are constrained or where heterogeneity across regions inhibits universal conclusions. Where appropriate, recommendations are couched in conditional terms and accompanied by suggested next steps for further targeted evidence generation or in-market validation.

Synthesis of strategic insights and closing perspectives that translate clinical, regulatory, and commercial intelligence into executable priorities for stakeholders

The concluding perspective synthesizes clinical, regulatory, and commercial insights into a coherent set of priorities for stakeholders invested in vaginitis therapeutics. Across therapeutic classes and routes of administration, the imperative is clear: therapies that demonstrate meaningful reductions in recurrence, improved tolerability, and alignment with patient preferences are most likely to achieve durable adoption. Implementing this requires an integrated approach that pairs rigorous clinical programs with real-world evidence collection and digital engagement strategies to support adherence and monitoring.

Operational resilience is equally essential; organizations must address supply chain fragility and tariff exposure through diversified sourcing, regional manufacturing options, and strategic inventory management. Commercially, segmentation-informed go-to-market strategies that consider route of administration, product type, distribution channel, and end-user demographics will sharpen targeting and reduce commercial waste. Finally, collaboration across industry, clinical societies, and payer stakeholders can accelerate development of standardized diagnostics and care pathways that benefit patients and streamline adoption.

Taken together, these priorities form a roadmap for translating scientific advances into tangible improvements in patient outcomes while preserving commercial viability in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of next-generation molecular diagnostics for precise vaginal microbiome profiling and treatment targeting
  • 5.2. Pipeline emphasis on live biotherapeutic products to restore healthy vaginal flora in recurrent vaginitis patients
  • 5.3. Increasing investment in boric acid and non-antibiotic boronate ester therapies for biofilm disruption
  • 5.4. Over-the-counter antifungal gel formulations enhanced with mucoadhesive polymers to improve patient adherence and efficacy
  • 5.5. Integration of telemedicine and digital symptom tracking apps to personalize vaginitis treatment pathways and outcomes
  • 5.6. Personalized therapy selection based on next-generation sequencing of vaginal microbiota and resistance gene profiling
  • 5.7. Regulatory approvals accelerating for non-hormonal microbiome restoration products targeting bacterial vaginosis recurrence prevention
  • 5.8. Clinical trials evaluating vaginal microbiota transplant efficacy as an alternative approach for refractory bacterial vaginosis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaginitis Therapeutics Market, by Treatment Type

  • 8.1. Antifungal Treatments
    • 8.1.1. Azoles
      • 8.1.1.1. Clotrimazole
      • 8.1.1.2. Fluconazole
      • 8.1.1.3. Miconazole
    • 8.1.2. Polyenes
      • 8.1.2.1. Amphotericin B
      • 8.1.2.2. Nystatin
  • 8.2. Probiotic Treatments

9. Vaginitis Therapeutics Market, by Route Of Administration

  • 9.1. Intravaginal
    • 9.1.1. Creams
    • 9.1.2. Gels
    • 9.1.3. Suppositories
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Gels
    • 9.3.3. Ointments

10. Vaginitis Therapeutics Market, by Product Type

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Vaginitis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Vaginitis Therapeutics Market, by End User Demographics

  • 12.1. Post-Menopausal Women
    • 12.1.1. Age 46-60
    • 12.1.2. Age 60+
  • 12.2. Pre-Menopausal Women
    • 12.2.1. Age 18-25
    • 12.2.2. Age 26-35
    • 12.2.3. Age 36-45
  • 12.3. Pregnant Women

13. Vaginitis Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vaginitis Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vaginitis Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. The Procter & Gamble Company
    • 16.3.3. Bayer Aktiengesellschaft
    • 16.3.4. Teva Pharmaceutical Industries Ltd.
    • 16.3.5. Viatris Inc.
    • 16.3.6. Dr. Reddy's Laboratories Ltd.
    • 16.3.7. Lupin Limited
    • 16.3.8. Glenmark Pharmaceuticals Ltd.
    • 16.3.9. Cipla Limited
    • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (US